Suchergebnisse - "Curtin, Nicola"

PubPharm (228)

21

DNA damage checkpoint kinases in cancer

enthalten in: Expert reviews in molecular medicine | 2020

von Smith, H. | Southgate, H. | Tweddle, D. | +1

22

ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms

enthalten in: Cancers | 2020

von Southgate, H. | Chen, L. | Tweddle, D. | +1

23

Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells

enthalten in: Cancers | 2020

von Smith, H. | Prendergast, L. | Curtin, N.

24

Targeting ATR as Cancer Therapy : A new era for synthetic lethality and synergistic combinations?

enthalten in: Pharmacology & therapeutics | 2020

von Bradbury, A. | Hall, S. | Curtin, N. | +1

25

The Development of Rucaparib/Rubraca® : A Story of the Synergy Between Science and Serendipity

enthalten in: Cancers | 2020

von Curtin, N.

26

CTRad 10 Years On : From 10-point Plan to Top 10 Achievements

enthalten in: Clinical oncology (Royal College of Radiologists (Great Britain)) | 2020

von Chalmers, A. | Chan, C. | Sebag-Montefiore, D. | +18

27

Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma

enthalten in: Frontiers in oncology | 2020

von Southgate, H. | Chen, L. | Curtin, N. | +1

28

Repositioning PARP inhibitors for SARS‐CoV‐2 infection(COVID‐19); a new multi‐pronged therapy for acute respiratory distress syndrome?

enthalten in: British Journal of Pharmacology | 2020

von Curtin, N. | Bányai, K. | Thaventhiran, J. | +3

29

Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy

enthalten in: Nature reviews. Clinical oncology | 2019

von Curtin, N. | Drew, Y. | Sharma-Saha, S.

CommentOn: Nature. 2019 Jul;571(7766):576-579. - PMID 31292550

30

Warburg and Krebs and related effects in cancer

enthalten in: Expert reviews in molecular medicine | 2019

von Unterlass, J. | Curtin, N.